Tubulin inhibitors

A patent survey

Kunal Nepali, Ritu Ojha, Sahil Sharma, Preet M.S. Bedi, Kanaya L. Dhar

Research output: Contribution to journalReview article

25 Citations (Scopus)

Abstract

Tubulin is one of the most useful and strategic molecular targets for anticancer drugs. The dynamic process of microtubule assembly and disassembly can be blocked by various agents that bind to distinct sites in the β-tubulin subunit. By interfering with microtubule function in vitro, these agents arrest cells in mitosis, eventually leading to cell death, by both apoptosis and necrosis. So far, three binding domains have been identified a) the colchicine site close to the α/β interface, b) the area where the vinca alkaloids bind, and c) the taxane-binding pocket. This review compiles the patent literature up to 2013 and offers a detailed account of all the advances on Tubulin inhibitors (lead molecules) along with in depth knowledge about the number of novel scaffolds, modified analogs and derivatives of the lead molecules. Colchicine binding site remains the most explored site indicated by the patent survey as majority of the patents revolves around phenstatin and combretastatin based molecules where the key structural feature for tubulin inhibition is an appropriate arrangement of the two aromatic rings at an appropriate distance and optimal dihedral angle maximizing interactions with tubulin. A brief account of promising tubulin inhibitors in stages of clinical development and some strategies for the development of potent molecules overcoming the problem of drug resistance have also been discussed.

Original languageEnglish
Pages (from-to)176-220
Number of pages45
JournalRecent Patents on Anti-Cancer Drug Discovery
Volume9
Issue number2
DOIs
Publication statusPublished - Jan 1 2014
Externally publishedYes

Fingerprint

Tubulin Modulators
Tubulin
Patents
Colchicine
Microtubules
Vinca Alkaloids
Literature
Mitosis
Drug Resistance
Cell Death
Necrosis
Binding Sites
Apoptosis
Surveys and Questionnaires
Pharmaceutical Preparations

Keywords

  • Cancer
  • Chalcones
  • Colchicine
  • Microtubules
  • Tubulin
  • Tumor

ASJC Scopus subject areas

  • Oncology
  • Drug Discovery
  • Cancer Research
  • Pharmacology (medical)

Cite this

Tubulin inhibitors : A patent survey. / Nepali, Kunal; Ojha, Ritu; Sharma, Sahil; Bedi, Preet M.S.; Dhar, Kanaya L.

In: Recent Patents on Anti-Cancer Drug Discovery, Vol. 9, No. 2, 01.01.2014, p. 176-220.

Research output: Contribution to journalReview article

Nepali, Kunal ; Ojha, Ritu ; Sharma, Sahil ; Bedi, Preet M.S. ; Dhar, Kanaya L. / Tubulin inhibitors : A patent survey. In: Recent Patents on Anti-Cancer Drug Discovery. 2014 ; Vol. 9, No. 2. pp. 176-220.
@article{aa995338f85046818bd04ad883f9c10e,
title = "Tubulin inhibitors: A patent survey",
abstract = "Tubulin is one of the most useful and strategic molecular targets for anticancer drugs. The dynamic process of microtubule assembly and disassembly can be blocked by various agents that bind to distinct sites in the β-tubulin subunit. By interfering with microtubule function in vitro, these agents arrest cells in mitosis, eventually leading to cell death, by both apoptosis and necrosis. So far, three binding domains have been identified a) the colchicine site close to the α/β interface, b) the area where the vinca alkaloids bind, and c) the taxane-binding pocket. This review compiles the patent literature up to 2013 and offers a detailed account of all the advances on Tubulin inhibitors (lead molecules) along with in depth knowledge about the number of novel scaffolds, modified analogs and derivatives of the lead molecules. Colchicine binding site remains the most explored site indicated by the patent survey as majority of the patents revolves around phenstatin and combretastatin based molecules where the key structural feature for tubulin inhibition is an appropriate arrangement of the two aromatic rings at an appropriate distance and optimal dihedral angle maximizing interactions with tubulin. A brief account of promising tubulin inhibitors in stages of clinical development and some strategies for the development of potent molecules overcoming the problem of drug resistance have also been discussed.",
keywords = "Cancer, Chalcones, Colchicine, Microtubules, Tubulin, Tumor",
author = "Kunal Nepali and Ritu Ojha and Sahil Sharma and Bedi, {Preet M.S.} and Dhar, {Kanaya L.}",
year = "2014",
month = "1",
day = "1",
doi = "10.2174/15748928113089990042",
language = "English",
volume = "9",
pages = "176--220",
journal = "Recent Patents on Anti-Cancer Drug Discovery",
issn = "1574-8928",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Tubulin inhibitors

T2 - A patent survey

AU - Nepali, Kunal

AU - Ojha, Ritu

AU - Sharma, Sahil

AU - Bedi, Preet M.S.

AU - Dhar, Kanaya L.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Tubulin is one of the most useful and strategic molecular targets for anticancer drugs. The dynamic process of microtubule assembly and disassembly can be blocked by various agents that bind to distinct sites in the β-tubulin subunit. By interfering with microtubule function in vitro, these agents arrest cells in mitosis, eventually leading to cell death, by both apoptosis and necrosis. So far, three binding domains have been identified a) the colchicine site close to the α/β interface, b) the area where the vinca alkaloids bind, and c) the taxane-binding pocket. This review compiles the patent literature up to 2013 and offers a detailed account of all the advances on Tubulin inhibitors (lead molecules) along with in depth knowledge about the number of novel scaffolds, modified analogs and derivatives of the lead molecules. Colchicine binding site remains the most explored site indicated by the patent survey as majority of the patents revolves around phenstatin and combretastatin based molecules where the key structural feature for tubulin inhibition is an appropriate arrangement of the two aromatic rings at an appropriate distance and optimal dihedral angle maximizing interactions with tubulin. A brief account of promising tubulin inhibitors in stages of clinical development and some strategies for the development of potent molecules overcoming the problem of drug resistance have also been discussed.

AB - Tubulin is one of the most useful and strategic molecular targets for anticancer drugs. The dynamic process of microtubule assembly and disassembly can be blocked by various agents that bind to distinct sites in the β-tubulin subunit. By interfering with microtubule function in vitro, these agents arrest cells in mitosis, eventually leading to cell death, by both apoptosis and necrosis. So far, three binding domains have been identified a) the colchicine site close to the α/β interface, b) the area where the vinca alkaloids bind, and c) the taxane-binding pocket. This review compiles the patent literature up to 2013 and offers a detailed account of all the advances on Tubulin inhibitors (lead molecules) along with in depth knowledge about the number of novel scaffolds, modified analogs and derivatives of the lead molecules. Colchicine binding site remains the most explored site indicated by the patent survey as majority of the patents revolves around phenstatin and combretastatin based molecules where the key structural feature for tubulin inhibition is an appropriate arrangement of the two aromatic rings at an appropriate distance and optimal dihedral angle maximizing interactions with tubulin. A brief account of promising tubulin inhibitors in stages of clinical development and some strategies for the development of potent molecules overcoming the problem of drug resistance have also been discussed.

KW - Cancer

KW - Chalcones

KW - Colchicine

KW - Microtubules

KW - Tubulin

KW - Tumor

UR - http://www.scopus.com/inward/record.url?scp=84901197312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901197312&partnerID=8YFLogxK

U2 - 10.2174/15748928113089990042

DO - 10.2174/15748928113089990042

M3 - Review article

VL - 9

SP - 176

EP - 220

JO - Recent Patents on Anti-Cancer Drug Discovery

JF - Recent Patents on Anti-Cancer Drug Discovery

SN - 1574-8928

IS - 2

ER -